Felix

📢 Heads up $FIO community Binance is delisting FIO on April 23rd. If you hold FIO there, withdraw before that date. FIO remains tradeable on 12+ exchanges - liquidity is intact. 🔵 Top CEXs: Gate. io, HTX, BTCC, MEXC, AscendEX, Bitrue 🟣 wFIO also live on Ethereum DEXs & Base Nothing changes on the protocol side. We're building. 🔨 Full markets 👇 coingecko.com/en/coins/fio-p…

@_PradeepGoel The real breakthrough is AI that adapts to us, not the other way around.

How we interact with AI is wrong in many ways. We're still using computer interfaces (text prompts, graphical interfaces) for a different kind of intelligence. The next breakthrough won't be in models but in interfaces. Imagine AI systems that understand intent rather than commands, that learn your communication style rather than forcing you to learn theirs, that anticipate needs rather than waiting for instructions. This interface evolution will make AI accessible to billions who find current approaches unnatural or intimidating.

The obsession with general AI is distracting us from the immediate opportunity, specialized intelligence ecosystems. We should be creating networks of specialized models that collaborate. This approach mirrors how human expertise works in the real world, through collaboration between specialists. It's more efficient, more transparent, and more adaptable than trying to build monolithic general models. We're already seeing this approach outperform general models in specific domains while requiring a fraction of the computational resources. The future is millions of specialized AIs working together.

Amazon Web Services has launched Amazon Bio Discovery, an AI platform designed to accelerate early stage drug discovery by letting scientists run complex research workflows without needing to build machine learning pipelines themselves. The system gives researchers access to biological foundation models that can generate and evaluate potential molecules, then route promising candidates to lab partners for synthesis and testing. In one reported use case, the platform helped generate hundreds of thousands of antibody candidates and narrow them rapidly for experimentation. What matters here is the removal of workflow friction. Drug discovery has never lacked ideas. It has lacked speed between idea, validation, iteration, and execution. Many labs can identify promising hypotheses, but turning them into testable pipelines requires fragmented tools, scarce technical talent, and slow handoffs between software and wet labs. That is where AI becomes most valuable, not as a scientist replacement, but as an orchestration layer for science. The next frontier in biotech may come from systems that connect modeling, experimentation, and feedback loops into one continuous engine. When AI can compress months of candidate generation into weeks, the real gain is not convenience, it is more shots on goal for scientific progress. This also signals that major cloud providers are moving beyond compute infrastructure into domain-specific AI operating systems for industries like healthcare, life sciences, and manufacturing. The highest value AI systems will be vertical systems that coordinate expertise, automate complexity, and keep humans in control of critical decisions.

AI job fears are colliding with hiring reality A recent debate questioned what happens to demand if AI replaces large parts of the workforce. In response, investor @aakashgupta pointed to active hiring at Anthropic, which still has dozens of open engineering roles. Even as @DarioAmodei warns that coding could be among the first areas disrupted, demand for developers continues to grow, with long-term projections trending upward. What’s emerging is a transition, not a clear outcome. AI is increasing output per worker, but also raising the bar for what “useful work” looks like. Roles aren’t disappearing uniformly, they’re shifting toward those who can design, guide, and work alongside these systems. The question is not how many jobs remain, but how work reorganizes itself around AI and who is positioned to move with that shift.

@joinFIO I agree!!!

Having a handle isn’t a feature It’s a baseline.

With a Power Node you can: • Run AI locally • Keep data private • Deploy agents • Participate in a decentralized network This is a different game.

Want to accept private crypto donations for your cause, charity, or community project? @CoinDonorApp makes it simple. Non-custodial fundraising that supports $ZANO, $fUSD, and Confidential Assets like $BTCx, $ETHx, and $BCHx. 🔹 Donations go directly to your wallet 🔹 Auto-detection for $ZANO and Confidential Assets incoming donations 🔹 Embeddable widget for any website 🔹 Set fundraising goals with a live tracker 🔹 Works with the Zano desktop/mobile, and @BitcoinCom wallet Fundraise privately at coindonor.com. Use code "ZANO" for 50% off. 🔒

Not everything you see online is “real” anymore… And the crazy part is, most people can’t even tell the difference now. But there are actually systems being built to verify what’s real again. Stay with me, let me walk you through.

PAIneer Dashboard Overview 👇 Your command center for sovereign AI infrastructure. 5 modules. Zero cloud dependency. Full control. Private AI. Intelligent agents. Decentralized compute. All in one dashboard. All under your control. #privateAI

Cloud AI has a bottleneck problem. Every inference crosses your firewall → external servers → queue → process → return. Edge AI eliminates the round-trip. But edge AI at scale needs a different architecture. 🧵

4 days left to enter the Zano x NanoGPT Contest! The bonus ZANO were all taken, but you can still win prizes from the $400 pool! 👇 🔹 Deposit $ZANO to @NanoGPTcom 🔹 Create any content/tool you’d like, doesn’t need to be strictly Zano related 🔹 Share with us (as a reply to the contest post) what you did, along with a brief explainer of why paying AI through private crypto like Zano matters Join here: x.com/zano_project/s…

The costs of centralized AI are becoming unsustainable. Beyond the obvious computational expenses, there's growing regulatory risk, user distrust, and innovation stagnation from homogenous data sources. Decentralized approaches are economically better. Early implementations show 40-60% reduction in training costs when leveraging distributed networks, along with higher model diversity and reduced regulatory risk. Centralization is a local maximum that's becoming a global minimum. AI economics should be distributed, collaborative, and contributor-empowered.

@joinFIO If you have a voice, use it.

If you’re holding FIO, this is your moment to shape what comes next. Vote like it matters. Because it does. 🗳️

The focus on model performance misses the bigger picture, the network effects of intelligence. A model that improves through contributions becomes more valuable as more people use it, creating a compounding advantage. This dynamic is different from traditional software where network effects are about user numbers. In AI, the network effect is about the collective intelligence that emerges from diverse contributions and applications.

Researchers at @MassGenBrigham have published a timely reminder, AI may be improving in medicine, but it still struggles with one of the most important parts of care, clinical reasoning. Using a new benchmark called PrIME-LLM, researchers tested 21 leading models across real diagnostic scenarios. While many models identified the correct final diagnosis once enough data was provided, they performed poorly in the earlier stages: generating differential diagnoses, deciding what to test, and reasoning through uncertainty. That distinction matters. Medicine is not just about arriving at an answer. It is about navigating incomplete information, weighing probabilities, ruling out risk, and updating decisions as new evidence emerges. In other words, healthcare depends less on prediction alone and more on structured judgment under uncertainty. This exposes a broader misconception in AI adoption, strong outputs do not always mean strong reasoning. A model can sound confident, reach the right endpoint, and still fail the process required to trust it in real-world environments. The opportunity, then, is not physician replacement. It is clinical augmentation. AI can accelerate documentation, summarize records, surface patterns, and support decision pathways. But the “art of medicine”—context, tradeoffs, accountability, and nuanced judgment, still requires human oversight. This reinforces a principle that extends beyond healthcare, high-stakes AI systems must be measured not only by outcomes, but by how they reason, how they justify decisions, and how reliably humans can govern them. Intelligence without oversight is not enough.

AI-driven automation is raising deeper economic concerns Mo Gawdat argued that as AI replaces cheap labor, it could undermine a core pillar of capitalism, consumer demand. At the same time, new research models this as a coordination problem. Firms automate to stay competitive, but if many do it at once, job losses can reduce spending across the economy, feeding back into weaker growth. Recent data reflects the tension, with large-scale layoffs and falling costs of automation accelerating adoption. Some see a path toward abundance and lower costs. Others worry about a mismatch between productivity gains and income distribution. If AI concentrates both production and ownership, the system becomes fragile. PAI3 approaches that layer by distributing AI workloads across user-owned nodes, widening participation in the value created by automation. As AI scales, the challenge may not just be efficiency, but maintaining balance between productivity and demand.